Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 6 of the 13 calendar months from Oct 2025 to Oct 2026: Dec 2025, Jan 2026, Feb 2026, Apr 2026, May 2026 and Sep 2026.
- Largest single sale: $1.6M (25,390 shares) of Travere Therapeutics, Inc. on Sep 15, 2026. Filing
- Last sale before this period: Jul 1, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | EVP, Head of R&D & CMO | Jan 4, 2022 | Sep 17, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 15, 2026, Travere Therapeutics, Inc.: sold 44,674 shares for $2.8M, under a disclosed plan; 32,395 shares acquired by exercising options. 1 filing: 1
- Jun 22, 2026, Travere Therapeutics, Inc.: 468 shares given away. 1 filing: 1
- May 6, 2026, Travere Therapeutics, Inc.: sold 311 shares for $14K, under a disclosed plan. 1 filing: 1
- May 5, 2026, Travere Therapeutics, Inc.: sold 2,174 shares for $101K, under a disclosed plan. 1 filing: 1
- May 4, 2026, Travere Therapeutics, Inc.: sold 20,000 shares for $900K, under a disclosed plan; 20,000 shares acquired by exercising options; 4,250 shares vested. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.